Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latrepirdine in mild to moderate Alzheimer's disease
NCT01066481Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Apr 2010
- Primary completion
- Mar 2012
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
01
Overview
A Phase 2 trial of latrepirdine in Alzheimer's disease (AD), sponsored by Pfizer. Planned start Apr 2010; status: withdrawn.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01066481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01066481.